Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;16(4):895-903.
doi: 10.1007/s11739-020-02528-4. Epub 2020 Oct 17.

Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study

Mariarosaria De Luca  1   2 , Giorgio Bosso  3 , Antonio Valvano  3 , Vincenzo Guardasole  1   2 , Amodio Botta  2 , Vincenzo Carbone  3 , Giovanni Carella  3 , Andrea Del Buono  2 , Giuseppe Di Giovanni  2 , Biagio Fimiani  3 , Franco Guarnaccia  3 , Emanuela Lapice  2 , Emilia Martedì  2 , Giuseppe Memoli  2 , Domenica Oliva  2 , Geremia Romano  2 , Antonio Cittadini  1 , Giovanni Battista Zito  3 , Ugo Oliviero  4   5
Affiliations

Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study

Mariarosaria De Luca et al. Intern Emerg Med. 2021 Jun.

Erratum in

Abstract

SCODIAC was a pilot study which revealed an increasing use of SGLT2i in 123 outpatients affected with Heart Failure (HF) and Type 2 Diabetes Mellitus. SCODIAC-II study, the second phase of the program, has been carried out to determine diagnostic and therapeutic pathways in a larger group of patients and to verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and cardiovascular therapies. 406 HF-diabetic patients, referred to Cardiologists and Diabetologists of pertaining healthcare districts in Campania, were enrolled in this retrospective study and divided in Group A, composed of 136 patients with preserved Ejection Fraction (HF-pEF)(> 45%) and Group B, formed of 270 patients with reduced EF (HF-rEF)(≤ 45%). All patients had performed periodic clinical and echocardiographic evaluations. The antidiabetic therapies resulted modified after 1 year with a greater use of GLP1-AR, gliptins and SGLT2i. Cardiovascular therapies resulted also modified with a greater use of sacubitril/valsartan and a reduction of ACEi and ARBs in HF-rEF patients. Echocardiography E velocity, A velocity and E/e' ratio resulted markedly reduced in 25 HF-pEF and in 60 HF-rEF patients treated with SGLT2i, in respect to both the whole sample of subjects at beginning and the other diabetic patients. LAVi resulted reduced only in HF-pEF patients and EF increased only in HF-rEF patients. The approach to the patients with HF and diabetes must necessarily take place in the healthcare districts, be multidisciplinary and integrated. SGLT2i could improve left ventricular function in HF-rEF patients and modify cardiovascular therapies, almost in this setting of patients.Trial registration The protocol was approved by the University of Naples Federico II Ethics Committee and registered at ClinicalTrial.gov (CT04375943). The principles outlined in the Declaration of Helsinki were followed.

Keywords: Diabetes; Echocardiography; Ejection fraction; Heart failure.

PubMed Disclaimer

References

    1. Virani SS, Alonso CA, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al (2020) heart disease and stroke statistics—2020 update a report from the American Heart Association. Circulation 141:e139–e596 - PubMed
    1. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A (2018) Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res 15:494–503 - DOI
    1. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34 - DOI
    1. Tarantini L, Di Lenarda A, Velussi M, Faggiano P, Comaschi M, Faglia E et al (2004) Diabetes mellitus, left ventricular dysfunction and congestive heart failure. Ital Heart J 5:605–615
    1. Botta A, Carbone V, Carella G, Del Buono A, De Luca M, Di Giovanni G et al (2019) Scompenso cardiaco nel paziente con diabete in Campania (SCODIAC). The Journal of AMD 4:219–229

LinkOut - more resources